Targeting adipose tissue

Diabetology and Metabolic Syndrome

Volumn 4, Issue 1, 2012, Pages

  Haas, Bodo ^a   Schlinkert, Paul ^b   Mayer, Peter ^a   Eckstein, Niels ^a  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b UNIVERSITY OF SALZBURG   (Austria)

Author keywords

'Brite' adipocytes; Brown adipose tissue; Positron emission tomography; Thermogenesis; Transdifferentiation; UCP1; White adipose tissue

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER; 6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; ADENOSINE TRIPHOSPHATE; AMRINONE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; ATRIAL NATRIURETIC FACTOR; BALAGLITAZONE; BILE ACID; BMP8B; BRAIN NATRIURETIC PEPTIDE; KB 141; LIOTHYRONINE; MRL 24; N [4 [2 [[2 HYDROXY 2 (3 PYRIDINYL)ETHYL]AMINO]ETHYL]PHENYL] 4 [4 [4 (TRIFLUOROMETHYL)PHENYL] 2 THIAZOLYL]BENZENESULFONAMIDE; OSTEOGENIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIMONABANT; SILDENAFIL; SOBETIROME; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VARDENAFIL;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; BIRTH; BROWN ADIPOSE TISSUE; CELL MATURATION; COLD ACCLIMATIZATION; DRUG TARGETING; ENERGY CONSUMPTION; HEAT; HOMEOSTASIS; HUMAN; LIPID DIET; METABOLIC SYNDROME X; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STARVATION; WHITE ADIPOSE TISSUE;

EID: 84867833007     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-4-43     Document Type: Article

References (85)

1. Adipose tissue as an endocrine organ. EE Kershaw, JS Flier, J Clin Endocrinol Metab 2004 89 2548 2556 10.1210/jc.2004-0395 15181022
2. Adipose tissue-derived factors: impact on health and disease. ME Trujillo, PE Scherer, Endocr Rev 2006 27 762 778 17056740
3. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. T Yamauchi, J Kamon, H Waki, Y Terauchi, N Kubota, K Hara, Y Mori, T Ide, K Murakami, N Tsuboyama-Kasaoka, et al. Nat Med 2001 7 941 946 10.1038/90984 11479627
4. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. PJ Havel, Curr Opin Lipidol 2002 13 51 59 10.1097/00041433-200202000-00008 11790963
5. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. GS Hotamisligil, NS Shargill, BM Spiegelman, Science 1993 259 87 91 10.1126/science.7678183 7678183
6. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. C Lagathu, L Yvan-Charvet, JP Bastard, M Maachi, A Quignard-Boulange, J Capeau, M Caron, Diabetologia 2006 49 2162 2173 10.1007/s00125-006-0335-z 16865359
7. The hormone resistin links obesity to diabetes. CM Steppan, ST Bailey, S Bhat, EJ Brown, RR Banerjee, CM Wright, HR Patel, RS Ahima, MA Lazar, Nature 2001 409 307 312 10.1038/35053000 11201732
8. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. J Spranger, A Kroke, M Mohlig, K Hoffmann, MM Bergmann, M Ristow, H Boeing, AF Pfeiffer, Diabetes 2003 52 812 817 10.2337/diabetes.52.3.812 12606524
9. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? A Rodriguez, V Catalan, J Gomez-Ambrosi, G Fruhbeck, Curr Pharm Des 2007 13 2169 2175 10.2174/ 138161207781039599 17627548
10. Saturated fatty acids and insulin resistance. M Funaki, J Med Invest 2009 56 88 92 10.2152/jmi.56.88 19763019
11. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. ND Oakes, PG Thalen, SM Jacinto, B Ljung, Diabetes 2001 50 1158 1165 10.2337/diabetes.50.5. 1158 11334421
12. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. JM Ye, N Dzamko, ME Cleasby, BD Hegarty, SM Furler, GJ Cooney, EW Kraegen, Diabetologia 2004 47 1306 1313 15232684
13. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. AM Sharma, B Staels, J Clin Endocrinol Metab 2007 92 386 395 17148564
14. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. JH Choi, AS Banks, JL Estall, S Kajimura, P Bostrom, D Laznik, JL Ruas, MJ Chalmers, TM Kamenecka, M Bluher, et al. Nature 2010 466 451 456 10.1038/nature09291 20651683
15. Benzoyl 2-methyl indoles as selective PPARgamma modulators. JJ Acton III, RM Black, AB Jones, DE Moller, L Colwell, TW Doebber, KL MacNaul, J Berger, HB Wood, Bioorg Med Chem Lett 2005 15 357 362 10.1016/j.bmcl.2004.10.068 15603954
16. NS-1: A novel partial peroxisome proliferator-activated receptor gamma agonist to improve insulin sensitivity and metabolic profile. S Chaudhary, A Dube, V Kothari, N Sachan, CD Upasani, Eur J Pharmacol 2012 684 154 160 10.1016/j.ejphar.2012.03.033 22484334
17. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (gamma) agonist. R Agrawal, P Jain, SN Dikshit, Mini Rev Med Chem 2012 12 87 97 10.2174/138955712798995048 22372600
18. Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. K Henriksen, I Byrjalsen, P Qvist, H Beck-Nielsen, G Hansen, BJ Riis, H Perrild, OL Svendsen, J Gram, MA Karsdal, et al. Diabetes Metab Res Rev 2011 27 392 401 10.1002/dmrr.1187 21328517
19. Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes. P Mayer, B Haas, J Celner, H Enzmann, A Pfeifer, Diabetes Obes Metab 2011 13 791 799 10.1111/j.1463-1326.2011.01409.x 21477042
20. Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects. H Van, F Lonnqvist, A Thorne, A Wennlund, V Large, S Reynisdottir, P Arner, Int J Obes Relat Metab Disord 1997 21 972 979 10.1038/sj.ijo.0800504 9368819
21. From PDE3B to the regulation of energy homeostasis. E Degerman, F Ahmad, YW Chung, E Guirguis, B Omar, L Stenson, V Manganiello, Curr Opin Pharmacol 2011 11 676 682 10.1016/j.coph.2011.09.015 22001403
22. Various phosphodiesterase subtypes mediate the in vivo antilipolytic effect of insulin on adipose tissue and skeletal muscle in man. S Enoksson, E Degerman, E Hagstrom-Toft, V Large, P Arner, Diabetologia 1998 41 560 568 10.1007/s001250050947 9628274
23. BAT: a new target for human obesity? G Fruhbeck, S Becerril, N Sainz, P Garrastachu, MJ Garcia-Velloso, Trends Pharmacol Sci 2009 30 387 396 10.1016/j.tips.2009.05.003 19595466
24. Brown adipose tissue: function and physiological significance. B Cannon, J Nedergaard, Physiol Rev 2004 84 277 359 10.1152/physrev.00015.2003 14715917
25. Developmental origin of fat: tracking obesity to its source. S Gesta, YH Tseng, CR Kahn, Cell 2007 131 242 256 10.1016/j.cell.2007.10.004 17956727
26. Mitochondrial uncoupling proteins in energy expenditure. LP Kozak, ME Harper, Annu Rev Nutr 2000 20 339 363 10.1146/annurev.nutr.20.1.339 10940338
27. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. W Cao, KW Daniel, J Robidoux, P Puigserver, AV Medvedev, X Bai, LM Floering, BM Spiegelman, S Collins, Mol Cell Biol 2004 24 3057 3067 10.1128/MCB.24.7.3057- 3067.2004 15024092
28. The brown adipose cell: a model for understanding the molecular mechanisms of insulin resistance. AM Valverde, M Benito, M Lorenzo, Acta Physiol Scand 2005 183 59 73 10.1111/j.1365-201X.2004.01384.x 15654920
29. Insulin: new roles for an ancient hormone. E Ferrannini, AQ Galvan, A Gastaldelli, S Camastra, AM Sironi, E Toschi, S Baldi, S Frascerra, F Monzani, A Antonelli, et al. Eur J Clin Invest 1999 29 842 852 10.1046/j.1365-2362.1999. 00536.x 10583426
30. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. C Weyer, C Bogardus, DM Mott, RE Pratley, J Clin Invest 1999 104 787 794 10.1172/JCI7231 10491414
31. Cyclic nucleotides converge on brown adipose tissue differentiation. PS Amieux, GS McKnight, Sci Signal 2010 3 2
32. Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesis. B Haas, P Mayer, K Jennissen, D Scholz, MB Diaz, W Bloch, S Herzig, R Fassler, A Pfeifer, Sci Signal 2009 2 a78 10.1126/scisignal.2000511 19952371
33. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. M Bordicchia, D Liu, EZ Amri, G Ailhaud, P Dessi-Fulgheri, C Zhang, N Takahashi, R Sarzani, S Collins, J Clin Invest 2012 122 1022 1036 10.1172/JCI59701 22307324
34. Deletion of inducible nitric-oxide synthase in leptin-deficient mice improves brown adipose tissue function. S Becerril, A Rodriguez, V Catalan, N Sainz, B Ramirez, M Collantes, I Penuelas, J Gomez-Ambrosi, G Fruhbeck, PLoS One 2010 5 10962 10.1371/journal.pone.0010962 20532036
35. Depressed thermogenesis but competent brown adipose tissue recruitment in mice devoid of all hormone-binding thyroid hormone receptors. V Golozoubova, H Gullberg, A Matthias, B Cannon, B Vennstrom, J Nedergaard, Mol Endocrinol 2004 18 384 401 14630998
36. Thermogenic mechanisms and their hormonal regulation. JE Silva, Physiol Rev 2006 86 435 464 10.1152/physrev.00009.2005 16601266
37. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. M Watanabe, SM Houten, C Mataki, MA Christoffolete, BW Kim, H Sato, N Messaddeq, JW Harney, O Ezaki, T Kodama, et al. Nature 2006 439 484 489 10.1038/nature04330 16400329
38. Using brown adipose tissue to treat obesity-the central issue. AJ Whittle, M Lopez, A Vidal-Puig, Trends Mol Med 2011 17 405 411 10.1016/j.molmed.2011.04.001 21602104
39. PTP1B regulates leptin signal transduction in vivo. JM Zabolotny, KK Bence-Hanulec, A Stricker-Krongrad, F Haj, Y Wang, Y Minokoshi, YB Kim, JK Elmquist, LA Tartaglia, BB Kahn, et al. Dev Cell 2002 2 489 495 10.1016/S1534-5807(02)00148-X 11970898
40. Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues. B Xue, T Pulinilkunnil, I Murano, KK Bence, H He, Y Minokoshi, K Asakura, A Lee, F Haj, N Furukawa, et al. Mol Cell Biol 2009 29 4563 4573 10.1128/MCB.01914-08 19528236
41. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. M Lopez, L Varela, MJ Vazquez, S Rodriguez-Cuenca, CR Gonzalez, VR Velagapudi, DA Morgan, E Schoenmakers, K Agassandian, R Lage, et al. Nat Med 2010 16 1001 1008 10.1038/nm.2207 20802499
42. BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. AJ Whittle, S Carobbio, L Martins, M Slawik, E Hondares, MJ Vazquez, D Morgan, RI Csikasz, R Gallego, S Rodriguez-Cuenca, et al. Cell 2012 149 871 885 10.1016/j.cell.2012.02.066 22579288
43. Identification and importance of brown adipose tissue in adult humans. AM Cypess, S Lehman, G Williams, I Tal, D Rodman, AB Goldfine, FC Kuo, EL Palmer, YH Tseng, A Doria, et al. N Engl J Med 2009 360 1509 1517 10.1056/NEJMoa0810780 19357406
44. Unexpected evidence for active brown adipose tissue in adult humans. J Nedergaard, T Bengtsson, B Cannon, Am J Physiol Endocrinol Metab 2007 293 444 E452 10.1152/ajpendo.00691.2006 17473055
45. Cold-activated brown adipose tissue in healthy men. WD van Marken Lichtenbelt, JW Vanhommerig, NM Smulders, JM Drossaerts, GJ Kemerink, ND Bouvy, P Schrauwen, GJ Teule, N Engl J Med 2009 360 1500 1508 10.1056/NEJMoa0808718 19357405
46. Functional brown adipose tissue in healthy adults. KA Virtanen, ME Lidell, J Orava, M Heglind, R Westergren, T Niemi, M Taittonen, J Laine, NJ Savisto, S Enerback, et al. N Engl J Med 2009 360 1518 1525 10.1056/ NEJMoa0808949 19357407
47. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. H Schoder, SM Larson, HW Yeung, J Nucl Med 2004 45 Suppl 1 72S 81S 14736838
48. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. TF Hany, E Gharehpapagh, EM Kamel, A Buck, J Himms-Hagen, GK Von Schulthess, Eur J Nucl Med Mol Imaging 2002 29 1393 1398 10.1007/s00259-002-0902-6 12271425
49. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. M Saito, Y Okamatsu-Ogura, M Matsushita, K Watanabe, T Yoneshiro, J Nio-Kobayashi, T Iwanaga, M Miyagawa, T Kameya, K Nakada, et al. Diabetes 2009 58 1526 1531 10.2337/db09-0530 19401428
50. Reduction of FDG uptake in brown adipose tissue by propranolol. H Jacobsson, M Bruzelius, SA Larsson, Eur J Nucl Med Mol Imaging 2005 32 1130 10.1007/s00259-005-1851-7 16133392
51. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. V Soderlund, SA Larsson, H Jacobsson, Eur J Nucl Med Mol Imaging 2007 34 1018 1022 10.1007/s00259-006-0318-9 17225118
52. The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. MC Zingaretti, F Crosta, A Vitali, M Guerrieri, A Frontini, B Cannon, J Nedergaard, S Cinti, FASEB J 2009 23 3113 3120 10.1096/fj.09-133546 19417078
53. White fat progenitor cells reside in the adipose vasculature. W Tang, D Zeve, JM Suh, D Bosnakovski, M Kyba, RE Hammer, MD Tallquist, JM Graff, Science 2008 322 583 586 10.1126/science.1156232 18801968
54. Beta-catenin activation is necessary and sufficient to specify the dorsal dermal fate in the mouse. R Atit, SK Sgaier, OA Mohamed, MM Taketo, D Dufort, AL Joyner, L Niswander, RA Conlon, Dev Biol 2006 296 164 176 10.1016/j.ydbio.2006.04.449 16730693
55. Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. JA Timmons, K Wennmalm, O Larsson, TB Walden, T Lassmann, N Petrovic, DL Hamilton, RE Gimeno, C Wahlestedt, K Baar, et al. Proc Natl Acad Sci U S A 2007 104 4401 4406 10.1073/pnas.0610615104 17360536
56. Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex. S Kajimura, P Seale, K Kubota, E Lunsford, JV Frangioni, SP Gygi, BM Spiegelman, Nature 2009 460 1154 1158 10.1038/nature08262 19641492
57. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. YH Tseng, E Kokkotou, TJ Schulz, TL Huang, JN Winnay, CM Taniguchi, TT Tran, R Suzuki, DO Espinoza, Y Yamamoto, et al. Nature 2008 454 1000 1004 10.1038/nature07221 18719589
58. PRDM16 controls a brown fat/skeletal muscle switch. P Seale, B Bjork, W Yang, S Kajimura, S Chin, S Kuang, A Scime, S Devarakonda, HM Conroe, H Erdjument-Bromage, et al. Nature 2008 454 961 967 10.1038/nature07182 18719582
59. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. J Wu, P Bostrom, LM Sparks, L Ye, JH Choi, AH Giang, M Khandekar, KA Virtanen, P Nuutila, G Schaart, et al. Cell 2012 150 366 376 10.1016/j.cell.2012.05.016 22796012
60. Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. H Oberkofler, G Dallinger, YM Liu, E Hell, F Krempler, W Patsch, J Lipid Res 1997 38 2125 2133 9374134
61. Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. A Vegiopoulos, K Muller-Decker, D Strzoda, I Schmitt, E Chichelnitskiy, A Ostertag, DM Berriel, J Rozman, AM de Hrabe, RM Nusing, et al. Science 2010 328 1158 1161 10.1126/science.1186034 20448152
62. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. P Bostrom, J Wu, MP Jedrychowski, A Korde, L Ye, JC Lo, KA Rasbach, EA Bostrom, JH Choi, JZ Long, et al. Nature 2012 481 463 468 10.1038/nature10777 22237023
63. PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. H Ohno, K Shinoda, BM Spiegelman, S Kajimura, Cell Metab 2012 15 395 404 10.1016/j.cmet.2012.01.019 22405074
64. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. A Aversa, M Caprio, A Antelmi, A Armani, M Brama, EA Greco, D Francomano, M Calanchini, G Spera, LL Di, et al. J Sex Med 2011 8 696 704 10.1111/j.1743-6109.2010.02152.x 21176111
65. Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis. C Moro, E Klimcakova, M Lafontan, M Berlan, J Galitzky, Br J Pharmacol 2007 152 1102 1110 17906676
66. Sildenafil promotes adipogenesis through a PKG pathway. X Zhang, J Ji, G Yan, J Wu, X Sun, J Shen, H Jiang, H Wang, Biochem Biophys Res Commun 396 1054 1059
67. Effects of type 5-phosphodiesterase inhibition on energy metabolism and mitochondrial biogenesis in human adipose tissue ex vivo. TL De, G Strapazzon, L Gianesello, N Caretta, C Pilon, A Bruttocao, C Foresta, J Endocrinol Invest 2011 34 738 741 22234177
68. Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism? A Armani, V Marzolla, GM Rosano, A Fabbri, M Caprio, Trends Endocrinol Metab 2011 22 404 411 10.1016/j.tem.2011.05.004 21741267
69. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. N Perwitz, J Wenzel, I Wagner, J Buning, M Drenckhan, K Zarse, M Ristow, W Lilienthal, H Lehnert, J Klein, Diabetes Obes Metab 2010 12 158 166 10.1111/j.1463-1326.2009.01133.x 19895638
70. Triiodothyronine induces UCP-1 expression and mitochondrial biogenesis in human adipocytes. JY Lee, N Takahashi, M Yasubuchi, YI Kim, H Hashizaki, MJ Kim, T Sakamoto, T Goto, T Kawada, Am J Physiol Cell Physiol 2012 302 463 C472 10.1152/ajpcell.00010.2011 22075692
71. Role of brown adipose tissue thermogenesis in overfeeding: a review. MJ Stock, NJ Rothwell, J R Soc Med 1983 76 71 73 6338229
72. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. V Ouellet, SM Labbe, DP Blondin, S Phoenix, B Guerin, F Haman, EE Turcotte, D Richard, AC Carpentier, J Clin Invest 2012 122 545 552 10.1172/JCI60433 22269323
73. Anatomical and Functional Assessment of Brown Adipose Tissue by Magnetic Resonance Imaging. YI Chen, AM Cypess, CA Sass, AL Brownell, KT Jokivarsi, CR Kahn, KK Kwong, Obesity (Silver Spring) 2012 20 1519 1526 10.1038/oby.2012.22
74. Cellular bioenergetics as a target for obesity therapy. YH Tseng, AM Cypess, CR Kahn, Nat Rev Drug Discov 2010 9 465 482 10.1038/nrd3138 20514071
75. The occurrence of brown adipose tissue in outdoor workers. P Huttunen, J Hirvonen, V Kinnula, Eur J Appl Physiol Occup Physiol 1981 46 339 345 10.1007/BF00422121 6266825
76. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists. JR Arch, Naunyn Schmiedebergs Arch Pharmacol 2008 378 225 240 10.1007/s00210-008-0271-1 18612674
77. Thermogenic and metabolic antiobesity drugs: rationale and opportunities. JC Clapham, JR Arch, Diabetes Obes Metab 2007 9 259 275 10.1111/j.1463-1326. 2006.00608.x 17391151
78. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. G Bryzgalova, S Effendic, A Khan, S Rehnmark, P Barbounis, J Boulet, G Dong, R Singh, S Shapses, J Malm, et al. J Steroid Biochem Mol Biol 2008 111 262 267 10.1016/j.jsbmb.2008.06.010 18621127
79. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. CM Villicev, FR Freitas, MS Aoki, C Taffarel, TS Scanlan, AS Moriscot, MO Ribeiro, AC Bianco, CH Gouveia, J Endocrinol 2007 193 21 29 10.1677/joe.1.07066 17400799
80. Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. N Petrovic, TB Walden, IG Shabalina, JA Timmons, B Cannon, J Nedergaard, J Biol Chem 2010 285 7153 7164 10.1074/jbc.M109.053942 20028987
81. C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. C Vernochet, SB Peres, KE Davis, ME McDonald, L Qiang, H Wang, PE Scherer, SR Farmer, Mol Cell Biol 2009 29 4714 4728 10.1128/MCB.01899-08 19564408
82. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. SR Smith, JL De, J Volaufova, Y Li, H Xie, GA Bray, Metabolism 2005 54 24 32 15877309
83. Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies. AJ Scheen, LG Van Gaal, JP Despres, X Pi-Sunyer, A Golay, C Hanotin, Rev Med Suisse 2006 2 1916 1923 16972542
84. Rimonabant for the treatment of obesity. A Samat, B Tomlinson, S Taheri, GN Thomas, Recent Pat Cardiovasc Drug Discov 2008 3 187 193 18991793
85. European Medicines Agency, The European Medicines Agency recommends suspension of the marketing authorization of Acomplia Doc. Ref.: EMEA/CHMP/537777/2008. Press release Oct 23. 2008 [http://www.emea.europa.eu]